Keywords: roche, xeloda, replace, 5-fu/lv, landmark, x-act, study

Roche's Xeloda "could replace 5-FU/LV"

Article | 11 July 2005

Print This

The landmark X-ACT study (Xeloda in Adjuvant Colon Cancer Therapy) shows that Roche's Xeloda (capecitabine) is an effective alternative to ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in